

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT

NEW DRUG APPLICATION OF STAPOKIBART INJECTION FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that the new drug application of Stapokibart injection for the treatment of chronic rhinosinusitis with nasal polyps has recently been accepted by the National Medical Products Administration (“**NMPA**”) and granted priority review. The relevant information is set out below:

- Drug name: Stapokibart injection
- Dosage form: Injection
- Application matter: New drug application for registration and marketing of domestically manufactured drugs
- Registration classification: Therapeutic biologics products, Class 1
- Applicant: Chengdu Kangnuoxing Biopharma, Inc. (成都康諾行生物醫藥科技有限公司), a wholly-owned subsidiary of the Company
- Acceptance No.: CXSS2400055
- Proposed indication: chronic rhinosinusitis with nasal polyps

The application is based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to confirm the efficacy and safety of Stapokibart injection in treatment of patients with chronic rhinosinusitis with nasal polyps. The study results showed that the data from the phase III clinical trial was positive with all the co-primary endpoints achieved, and showed highly significant statistical differences and demonstrated a favorable safety profile.

About Stapokibart

Stapokibart (R&D codename: CM310) is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4R α), and is the first domestically manufactured IL-4R α antibody drug receiving clinical trial approval from the NMPA. By targeting IL-4R α , Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart has shown a good safety profile and encouraging efficacy in a number of previous clinical trials. As of the date of this announcement, its new drug applications for the treatment of moderate-to-severe atopic dermatitis in adults and seasonal allergic rhinitis have been accepted by the NMPA.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize Stapokibart successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, June 7 2024

As at the date of this announcement, the Board of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive directors.